Potential Down’s syndrome treatment may improve cognition through epigenetic activity in brain

by Centre for Genomic Regulation

4 years ago
Down's Syndrome, epigenetics, brain, learning, memory, cognitive stimulation

Down’s syndrome is one of the most common causes of learning disabilities. Caused by the presence of all or part of a third copy of chromosome 21, it is a genetic disorder with no known cure or trea...

ORYZON presents efficacy and safety results of its CLEPSIDRA trial with iadademstat in ED-SCLC patients at ESMO-2020

by Oryzon Genomics

4 years ago
lung cancer, CLEPSIDRA, iadademstat, ESMO, epigenetics, drugs

Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announces today...

ORYZON to present at upcoming international conferences

by Oryzon Genomics

4 years ago
epigenetics, biopharmaceutical, conferences, CLEPSIDRA

ORYZON First Half Ended June 30, 2020 Results and Corporate Update

by Oryzon Genomics

4 years ago
Oryzon, results, epigenetics, biotechnology, Iadademstat, Vafidemstat

ORYZON presents final data from its Phase IIa clinical trial REIMAGINE at the 28th European Congress of Psychiatry, EPA 2020

by Oryzon Genomics

4 years ago
epigenetics, clinical trial, Vafidemstat, REIMAGINE, Psychiatry

ORYZON raises its share capital

by Oryzon Genomics

4 years ago
Oryzon, biopharmaceutical, epigenetics, capital

Oryzon Genomics, S.A. (MAD: ORY) ("Oryzon" or the "Company"), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical needs, today ...

ORYZON to present data from ETHERAL Phase IIa trial at the 2019 Alzheimer's Association International Conference in Los Angeles

by Oryzon Genomics

5 years ago
ETHERAL, clinical trial, Alzheimer, epigenetics

Oryzon Genomics, S.A.(ISIN Code: ES0167733015, ORY), a public clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announced...

Oryzon announces First-Patients-in in CLEPSIDRA: a Phase IIa clinical trial with Iadademstat (ORY-1001) in Small Cell Lung Cancer patients

by Oryzon Genomics

5 years ago
epigenetics, therapies, serious diseases, treatments, patients, ORY-1001, small cell lung cancer, SCLC, CLEPSIDRA

Oryzon Genomics has announced today the inclusion of the first two p atient s in a Phase IIa clinical study with Iadademstat (ORY - 1001) in Small Cell Lung Cancer (SCLC) patients .

TERRAs, the long non-coding RNAs that protect telomeres, are important epigenetic regulators

by CNIO - Centro Nacional de Investigaciones Oncológicas

6 years ago
telomeres, telomeric heterochromatin, TERRAs, Polycomb complex, epigenetics, RNAs

These novel telomere components are involved in the compaction of telomeric heterochromatin. TERRAs regulate the epigenetic state of telomeres by acting on the Polycomb complex

IDIBELL scientists identify a key regulator of the acquisition of immune tolerance to tumor cells in cancer patients

by IBEC - Institut de Bioenginyeria de Catalunya

7 years ago
immune cells, epigenetics, cancer

Researchers of the Chromatin and Disease Group from the Bellvitge Biomedical Research Institute (IDIBELL) in Barcelona have identified a distinctive epigenetic event in immune cells that differentiate...

Link between defects in DNA replication and loss of heterochromatin

by Centre for Genomic Regulation

7 years ago
cell division, epigenetics, DNA

Scientists reveal that a fault in the process that copies DNA during cell division can cause epigenetic changes that may be inherited for up-to five generations. They also identified the cause of thes...

ORYZON announces new grant from Alzheimer’s Drug Discovery Foundation (ADDF) to develop a companion marker for its ORY-2001 epigenetic drug

by Oryzon Genomics

7 years ago
Oryzon, clinical trial, Alzheimer’s Drug Discovery Foundation, ORY - 2001, epigenetics

Oryzon is finishing an on going double - blind, placebo - controlled Phase 1 clinical trial in healthy volunteer s of its proprietary oral LSD1 - MAOB dual selective inhibitor ORY - 2001. The company ...